Oscar Health, Inc. (OSCR)
| Market Cap | 10.74B +121.5% |
| Revenue (ttm) | 15.32B +42.8% |
| Net Income | 550.74M |
| EPS | 1.91 |
| Shares Out | 308.33M |
| PE Ratio | 18.24 |
| Forward PE | 19.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 505,177 |
| Open | 34.70 |
| Previous Close | 34.01 |
| Day's Range | 34.35 - 35.01 |
| 52-Week Range | 10.69 - 34.93 |
| Beta | 2.47 |
| Analysts | Hold |
| Price Target | 36.40 (+4.52%) |
| Earnings Date | Nov 5, 2026 |
About OSCR
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health prod... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for OSCR stock is "Hold." The 12-month stock price target is $36.4, which is an increase of 4.52% from the latest price.
News
Oscar Health price target raised to $36 from $26 at UBS
UBS raised the firm’s price target on Oscar Health (OSCR) to $36 from $26 and keeps a Neutral rating on the shares. The firm expects Oscar Health to post a…
Oscar Health, Inc. 2026 Third Quarter Earnings Conference Call
NEW YORK--(BUSINESS WIRE)--Oscar Health will release its third quarter 2026 financial results on Thursday, November 5, 2026.
Oscar Health put volume heavy and directionally bearish
Bearish flow noted in Oscar Health (OSCR) with 5,772 puts trading, or 1.5x expected. Most active are 10/9 weekly 29 puts and 10/2 weekly 34 calls, with total volume in…
Oscar Health initial stock reaction on CMS news overdone, says Raymond James
Raymond James reiterated an Outperform rating and $42 price target on Oscar Health (OSCR) after the Centers for Medicare & Medicaid Services announced ACA Marketplace program-integrity actions, includ...
Oscar Health Announces Thrive Capital's Completion of Oscar Health Common Stock Distribution to its Limited Partners
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar Health” or the “Company”) (NYSE: OSCR) announced that on September 18, 2026 certain funds affiliated with or advised by Thrive Capital Management,...
Oscar Health price target raised to $42 from $34 at Raymond James
Raymond James raised the firm’s price target on Oscar Health (OSCR) to $42 from $34 and keeps an Outperform rating on the shares. Management raised its long-term outlook with a…
Oscar Health price target raised to $30 from $28 at BofA
BofA raised the firm’s price target on Oscar Health (OSCR) to $30 from $28 and keeps an Underperform rating on the shares after the company updated their 2026 guidance to…
Oscar Health price target raised to $33 from $27 at Baird
Baird analyst Michael Ha raised the firm’s price target on Oscar Health (OSCR) to $33 from $27 and keeps a Neutral rating on the shares. The firm updated its model…
Oscar Health price target raised to $34 from $30 at Goldman Sachs
Goldman Sachs analyst Scott Fidel raised the firm’s price target on Oscar Health (OSCR) to $34 from $30 and keeps a Neutral rating on the shares. Oscar Health’s Investor Day…
Oscar Health increased earnings from operations outlook at investor day
Oscar Health (OSCR) yesterday discussed its financial performance and outlook at the company’s investor day, including the following improvements to its full year 2026 guidance: Medical loss ratio bet...
Oscar Health price target raised to $49 from $39 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on Oscar Health (OSCR) to $49 from $39 and keeps an Overweight rating on the shares following the investor day. Oscar…
Oscar Health Transcript: Investor Day 2026
Raised 2026 earnings guidance to $600M–$800M and reaffirmed long-term targets of 20%+ revenue CAGR, 5%–7% margins, and $4+ EPS by 2029. Growth will be driven by ACA expansion, Choice adoption, AI-driven efficiencies, and the Lucie Health Marketplace, with significant investments in technology and product innovation.
Oscar Health Slides: FY 2026
Oscar Health has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 16, 2026.
As Health Insurers Gain Handle On Costs, Stocks Are Soaring Again
Following a parade of health insurance company earnings reports this summer, stocks are rising and costs appear to be under control for now.
Oscar Health price target raised to $30 from $22 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Oscar Health (OSCR) to $30 from $22 and keeps a Neutral rating on the shares. The company’s stronger than expected Q2 results…
Oscar Health price target raised to $27 from $20 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Oscar Health (OSCR) to $27 from $20 and keeps an Equal Weight rating on the shares. While 1H26 results…
Oscar Health price target raised to $26 from $20 at UBS
UBS raised the firm’s price target on Oscar Health (OSCR) to $26 from $20 and keeps a Neutral rating on the shares.
Oscar Health price target raised to $27 from $19 at Baird
Baird raised the firm’s price target on Oscar Health (OSCR) to $27 from $19 and keeps a Neutral rating on the shares. The firm said there were alot of moving…
Oscar Health price target raised to $39 from $35 at Barclays
Barclays raised the firm’s price target on Oscar Health (OSCR) to $39 from $35 and keeps an Overweight rating on the shares post the Q2 report. The firm believes the…
Oscar Health price target raised to $25 from $13 at BofA
BofA analyst Adam Ron raised the firm’s price target on Oscar Health (OSCR) to $25 from $13 and keeps an Underperform rating on the shares. A “strong” Q2 “puts a…
GoodRx and Oscar Health Tout Tech as Consumer Needs Change
The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitabilit...
Oscar Health price target raised to $39 from $35 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on Oscar Health (OSCR) to $39 from $35 and keeps an Overweight rating on the shares.
Oscar Health Earnings Call Transcript: Q2 2026
Record Q2 results featured 70% revenue growth, a 46% membership increase, and significant margin expansion. Full-year guidance was raised on strong operating performance, with technology and AI driving efficiencies and cost savings.
Oscar Health Earnings release: Q2 2026
Oscar Health released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Oscar Health Quarterly report: Q2 2026
Oscar Health has published its Q2 2026 quarterly earnings report on August 6, 2026.